And no one is more ready to make it happen than Sanofi CEO Paul Hudson. Last week, Hudson proudly announced his company’s new ...

Sanofi’s CEO Paul Hudson has courted controversy by saying the French pharma’s potential COVID-19 vaccine will likely be delivered to the US government first should it succeed in clinical trials.

For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. | For GSK CEO Emma Walmsley, ...

Sanofi CEO Paul Hudson stated: “We achieved double-digit sales growth in 2024 while pursuing the transformation of the company. Innovation was a key driver of our growth as launches already ...

Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.

Along with Le Fur – who was CEO at Sanofi predecessor Sanofi-Aventis in 2007 and 2008 – eureKING's backers include Michael Kloss, former head of Panasonic Healthcare, who will serve as CEO of ...

Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...

The company in 2022 hired as its top boss former Sanofi CEO Christopher Viehbacher, who launched a $1 billion cost-savings plan and entered deals such as its $6.5 billion acquisition of Reata ...

The company's molecular research and drug-development platform taps what it calls nature's wisdom to drive the discovery of ...

Gain insights into Recursion Pharmaceuticals' Q4 2024 earnings call. Discover clinical advancements, key partnerships, and strategic plans for 2025.

Sanofi CEO Paul Hudson stated: “We achieved double-digit sales growth in 2024 while pursuing the transformation of the company. Innovation was a key driver of our growth as launches already ...